658 related articles for article (PubMed ID: 18559986)
1. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
2. Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia.
Feng JQ; Clinkenbeard EL; Yuan B; White KE; Drezner MK
Bone; 2013 Jun; 54(2):213-21. PubMed ID: 23403405
[TBL] [Abstract][Full Text] [Related]
3. A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice.
Ichikawa S; Gerard-O'Riley RL; Acton D; McQueen AK; Strobel IE; Witcher PC; Feng JQ; Econs MJ
Endocrinology; 2017 Mar; 158(3):470-476. PubMed ID: 28005411
[TBL] [Abstract][Full Text] [Related]
4. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Rowe PS
Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.
Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD
Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691
[TBL] [Abstract][Full Text] [Related]
6. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
7. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.
Martin A; Liu S; David V; Li H; Karydis A; Feng JQ; Quarles LD
FASEB J; 2011 Aug; 25(8):2551-62. PubMed ID: 21507898
[TBL] [Abstract][Full Text] [Related]
8. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism.
Feng JQ; Ward LM; Liu S; Lu Y; Xie Y; Yuan B; Yu X; Rauch F; Davis SI; Zhang S; Rios H; Drezner MK; Quarles LD; Bonewald LF; White KE
Nat Genet; 2006 Nov; 38(11):1310-5. PubMed ID: 17033621
[TBL] [Abstract][Full Text] [Related]
9. FGF23 directly inhibits osteoprogenitor differentiation in Dmp1-knockout mice.
Courbon G; Kentrup D; Thomas JJ; Wang X; Tsai HH; Spindler J; Von Drasek J; Ndjonko LM; Martinez-Calle M; Lynch S; Hivert L; Wang X; Chang W; Feng JQ; David V; Martin A
JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37943605
[TBL] [Abstract][Full Text] [Related]
10. Phosphate homeostasis and genetic mutations of familial hypophosphatemic rickets.
Razali NN; Hwu TT; Thilakavathy K
J Pediatr Endocrinol Metab; 2015 Sep; 28(9-10):1009-17. PubMed ID: 25894638
[TBL] [Abstract][Full Text] [Related]
11. Familial hypophosphatemic rickets caused by a large deletion in PHEX gene.
Saito T; Nishii Y; Yasuda T; Ito N; Suzuki H; Igarashi T; Fukumoto S; Fujita T
Eur J Endocrinol; 2009 Oct; 161(4):647-51. PubMed ID: 19581284
[TBL] [Abstract][Full Text] [Related]
12. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
Ichikawa S; Austin AM; Gray AK; Econs MJ
J Bone Miner Res; 2012 Feb; 27(2):453-60. PubMed ID: 22006791
[TBL] [Abstract][Full Text] [Related]
13. The wrickkened pathways of FGF23, MEPE and PHEX.
Rowe PS
Crit Rev Oral Biol Med; 2004 Sep; 15(5):264-81. PubMed ID: 15470265
[TBL] [Abstract][Full Text] [Related]
14. Osteocytes and the pathogenesis of hypophosphatemic rickets.
Yamazaki M; Michigami T
Front Endocrinol (Lausanne); 2022; 13():1005189. PubMed ID: 36246908
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization.
Liu S; Gupta A; Quarles LD
Curr Opin Nephrol Hypertens; 2007 Jul; 16(4):329-35. PubMed ID: 17565275
[TBL] [Abstract][Full Text] [Related]
16. Mineralized tissues in hypophosphatemic rickets.
Robinson ME; AlQuorain H; Murshed M; Rauch F
Pediatr Nephrol; 2020 Oct; 35(10):1843-1854. PubMed ID: 31392510
[TBL] [Abstract][Full Text] [Related]
17. [Osteocyte and DMP1].
Toyosawa S; Oya K; Sato S; Ishida K
Clin Calcium; 2012 May; 22(5):713-20. PubMed ID: 22549196
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.
Wöhrle S; Henninger C; Bonny O; Thuery A; Beluch N; Hynes NE; Guagnano V; Sellers WR; Hofmann F; Kneissel M; Graus Porta D
J Bone Miner Res; 2013 Apr; 28(4):899-911. PubMed ID: 23129509
[TBL] [Abstract][Full Text] [Related]
19. Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1).
Bai X; Levental M; Karaplis AC
J Clin Endocrinol Metab; 2022 Sep; 107(10):2777-2783. PubMed ID: 35896139
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic role of Fgf23 in Hyp mice.
Liu S; Zhou J; Tang W; Jiang X; Rowe DW; Quarles LD
Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E38-49. PubMed ID: 16449303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
